Immix Biopharma announces NXC-201 trial met primary endpoint

Immix Biopharma (IMMX) announced meeting its primary endpoint of complete response rate for cell therapy NXC-201 at an oral presentation of interim results at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. The oral presentation summarized meeting its interim results endpoint in from the U.S. multi-site NEXICART-2 clinical trial evaluating NXC-201 in relapsed/refractory AL Amyloidosis with a data cutoff of April 11. Prior to NXC-201 treatment, the median lines of therapy was 4. All patients had baseline relapsed/refractory AL Amyloidosis organ involvement. After NXC-201 treatment, all patients normalized pathological disease markers. Complete responses were observed in 70% of patients treated with NXC-201. The remaining three patients are bone marrow minimum residual disease negative, predicting future CR. Downstream clinical improvement, including cardiac and renal organ responses, were recorded after CRs. There have been no relapses recorded to-date and no safety signals identified. No neurotoxicity has been observed. Only low-grade cytokine release syndrome has been observed. The ASCO presentation contains clinical data as of April 11. Current treatments typically result in a lower than 10% complete response rate in relapsed/refractory AL Amyloidosis according to Zanwar, et al 2024, indicating a high unmet medical need. A key opinion leader event to discuss the significance will be held Tuesday, June 3.